FIELD: chemistry of peptides, medicine.
SUBSTANCE: invention relates to compound of the structure: N-methyl-(D-Leu-D-Val-D-Phe-D-Phe-D-leu)-NH2 designated for using as an active component in manufacturing a medicinal agent used for inhibition of natural β-amyloid peptides aggregation in patients suffering with disorder associated with β-amyloidosis and in treatment of Alzheimer's disease. Also, invention relates to a pharmaceutical composition, a method for inhibition of natural β-amyloid peptides, a method for detection of natural β-amyloid, a method for detection for the presence or absence of natural β-amyloid peptides in biological sample and to a method for treatment of patient with disorder associated with β-amyloidosis.
EFFECT: improved method for detecting, valuable medicinal properties of agent.
14 cl, 5 tbl, 5 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| STRUCTURAL PEPTIDE INHIBITORS OF α-SYNUCLEIN AGGREGATION | 2017 |
|
RU2766711C2 |
| ANTI-AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES POSSESSING THERAPEUTIC PROPERTIES | 2006 |
|
RU2551782C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| IMMUNOGENIC PRODUCTS OBTAINED BASED ON AMINO ACID SEQUENCES OF MUTEIN AMYLOID β (Aβ) AND THEIR APPLICATION METHODS | 2015 |
|
RU2750268C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
